Figure 2From: Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case reportDisease course and treatment response. The timeline from presentation detailing platelet and lactate dehydrogenase (LDH) response to plasma exchange (PE) and eculizumab (Ecu).Back to article page